NOTE: ALL STOCKS IN THIS WATCHLIST ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE. ANY TECHNICAL ANALYSIS IS PROVIDED IN THE CHART. PLEASE DO YOUR OWN DUE DILIGENCE BEFORE CONSIDERING INVESTING IN THESE STOCKS. (The Shares Float is based on figures from FinViz.Com).
Stocks highlighted in this watchlist include: $GRPN, $NEOT, $TRXC, $OPGN
GRPN: Float of 382.80 million shares with 9.76 short. Positive initiation from Gabelli & Co. Analyst Matthew Trusz launched coverage of the stock with a Buy recommendation and a $7 target price. The online-deals company is in the midst of rolling out a pair of products don’t require customers to show coupons before getting deals, and these have Wall Street analysts excited.He sees five main catalysts:
1. First is the fact that it has 32 million customers in North America, and that base is growing at a 15% annualized rate.
2. He applauds the new management's revitalized marketing push, which have led to six million organic net customer additions in the last six quarters.
3. Likes its link to local commerce and writes that its card-linked offers are a "game changer:"
4, Groupon's free cash flow is growing by nearly 20% per year.
5. The shares are "compellingly undervalued."
NEOT: This stock was alerted as a swing for October 10th on this watchlist. It has filled the gap yet. I still believe there is another 40% more gain available, maybe more. Finviz has a price target of $3
Neothetics, Inc. and Evofem Biosciences, Inc. Announce Merger Agreement to Create Women’s Health Company. The merger will position the combined company with an opportunity to become a leading women’s health company that develops and commercializes novel products. “This merger and concurrent financing provides continued funding for Evofem Biosciences’ ongoing Phase III study of Amphora® as a vaginal contraceptive – AMPOWER. We expect to close the study database and file for FDA review in the second quarter of 2019,” said Saundra Pelletier, Chief Executive Officer of Evofem Biosciences. “In addition, we have expanded our Amphora® clinical development platform with potential supplemental indications which would further strengthen its position as a cornerstone therapy in hormone-free birth control and as a preventative option for certain sexually transmitted infections.”
TRXC The story around this stock is too good to let go off.
Intuitive Surgical's (NASDAQ: ISRG) robots enjoy a near monopoly in hospitals, but that could change following last week's FDA approval of TransEnterix's (NYSEMKT: TRX) Senhance. Senhance is a robotic system that assists surgeons performing laparoscopic surgeries. It offers advantages, including haptic feedback, that could differentiate it from Intuitive Surgical's da Vinci system. Will TransEnterix carve out a meaningful slice of this fast-growing market?
Note that it's competition, ISRG, is now priced at $356 per share. Just saying....
OPGN: Float of 43.15 million shares with 9.14% short. The company announced that Evan Jones, the Company’s Chairman and Chief Executive Officer, will present a corporate overview at the Dawson James Securities 3rd Annual Small Cap Growth Conference on Thursday, October 19, 2017 at 9:00 a.m. Eastern time. The conference will be held at the Wyndham Grand Hotel in Jupiter, Florida on October 18-19, 2017.
In addition, Mr. Jones will participate on a panel discussion titled "The Convergence of Artificial Intelligence and Healthcare: New Developments in Precision Medicine” on Wednesday, October 18, 2017 at 5:00 p.m. Eastern time.